ArticleFrontiers in public health2026
Financing assistive technology-Policy options on the path towards universal health coverage.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Supporting functional ability in everyday life is essential for advancing toward universal health coverage (UHC). However, of the estimated 2.5 billion people in need of assistive technology (AT) globally, the vast majority do not have access. The main reason for this is financial barriers, particularly in low- and middle-income countries. This study aims to identify financing policy options for increasing access to affordable AT. The UHC concept, more specifically the three coverage dimensions-population, interventions (products and services), and costs, is used to descriptively analyze gaps in coverage related to affordability. The advantages and disadvantages of commonly practiced policy options, supported by global evidence, are explained and illustrated with country examples, resulting in structured guidance for both governmental and non-governmental policy stakeholders. When countries prioritize more strategically across the three coverage dimensions, financial resources can be targeted more effectively and have a greater impact. In addition, transparency about public financial commitments makes it easier for the non-government sector to contribute. Hence, public financing for AT is not only about raising more much-needed funds. There are also opportunities to increase access by designing publicly funded coverage transparently and guide the large non-governmental sector to be more effective in covering gaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.